These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10223401)

  • 21. Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients.
    Deutschländer A; la Fougère C; Boetzel K; Albert NL; Gildehaus FJ; Bartenstein P; Xiong G; Cumming P
    Neuroimage Clin; 2016; 12():41-6. PubMed ID: 27408789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacological profiles and clinical effects of antiparkinsonian agent, pramipexole].
    Kohno Y; Takeuchi S
    Nihon Yakurigaku Zasshi; 2004 Jun; 123(6):429-40. PubMed ID: 15170083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
    Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
    Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures.
    Ling ZD; Robie HC; Tong CW; Carvey PM
    J Pharmacol Exp Ther; 1999 Apr; 289(1):202-10. PubMed ID: 10087005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors.
    Svensson K; Carlsson A; Huff RM; Kling-Petersen T; Waters N
    Eur J Pharmacol; 1994 Oct; 263(3):235-43. PubMed ID: 7843260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
    Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
    BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved therapies for Parkinson's disease: life beyond dopamine D2/D3 receptor agonists.
    Williams M; Wright S; Lloyd GK
    Trends Pharmacol Sci; 1997 Sep; 18(9):307-10. PubMed ID: 9345846
    [No Abstract]   [Full Text] [Related]  

  • 28. New pharmacotherapy for Parkinson's disease.
    Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
    Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of repeated treatment with pramipexole on the central dopamine D3 system.
    Maj J; Rogói Z; Margas W; Kata M; Dziedzicka-Wasylewska M
    J Neural Transm (Vienna); 2000; 107(12):1369-79. PubMed ID: 11458990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: parallel observations from co-transfected human and native cerebral receptors.
    Aloisi G; Silvano E; Rossi M; Millan MJ; Maggio R
    Neuropharmacology; 2011; 60(2-3):439-45. PubMed ID: 21035472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole.
    Joyce JN; Presgraves S; Renish L; Borwege S; Osredkar T; Hagner D; Replogle M; PazSoldan M; Millan MJ
    Exp Neurol; 2003 Nov; 184(1):393-407. PubMed ID: 14637109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Locomotor hypoactivity and motor disturbances--behavioral effects induced by intracerebellar microinjections of dopaminergic DA-D2/D3 receptor agonists.
    Kolasiewicz W; Maj J
    Pol J Pharmacol; 2001; 53(5):509-15. PubMed ID: 11990070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G;
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inability of (-)deprenyl to modify copulatory performance in the male rat, whether or not stimulated by the selective D2 dopamine agonist SND 919.
    Ferrari F; Giuliani D
    Pharmacol Res; 1994; 29(4):373-82. PubMed ID: 7971689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
    Dooley M; Markham A
    Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pramipexole, a Dopamine D2/D3 Receptor-Preferring Agonist, Prevents Experimental Autoimmune Encephalomyelitis Development in Mice.
    Lieberknecht V; Junqueira SC; Cunha MP; Barbosa TA; de Souza LF; Coelho IS; Santos AR; Rodrigues AL; Dafré AL; Dutra RC
    Mol Neurobiol; 2017 Mar; 54(2):1033-1045. PubMed ID: 26801190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pramipexole in the treatment of advanced Parkinson's disease.
    Möller JC; Oertel WH
    Eur J Neurol; 2000 May; 7 Suppl 1():21-5. PubMed ID: 11054155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection.
    Le WD; Jankovic J; Xie W; Appel SH
    J Neural Transm (Vienna); 2000; 107(10):1165-73. PubMed ID: 11129106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.
    JAMA; 1997 Jul; 278(2):125-30. PubMed ID: 9214527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.